Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Immunome (IMNM) Accumulated Depreciation & Amortization (2023 - 2025)

Immunome's Accumulated Depreciation & Amortization history spans 3 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 34.13% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $6.4 million, up 34.13%, while the annual FY2025 figure was $6.4 million, 34.13% up from the prior year.
  • Accumulated Depreciation & Amortization reached $6.4 million in Q4 2025 per IMNM's latest filing, up from $4.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.4 million in Q4 2025 to a low of $3.9 million in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 3 years is $5.0 million, with a median of $4.7 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 21.52% in 2024, then surged 34.13% in 2025.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $3.9 million in 2023, then increased by 21.52% to $4.7 million in 2024, then skyrocketed by 34.13% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Accumulated Depreciation & Amortization are $6.4 million (Q4 2025), $4.7 million (Q4 2024), and $3.9 million (Q4 2023).